Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
Primary Purpose
Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Open-label flexibly dosed milnacipran
Sponsored by

About this trial
This is an interventional treatment trial for Knee Pain After Total Knee Arthroplasty focused on measuring Knee, Pain, Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Subject is a male or female adult outpatient age 18 or older at the time of consent.
- Subject has chronic persistent pain 1 year after TKA without history of new injury, infection, or implant failure.
- Subject has VAS > or = 40 mm at screen and baseline visits.
- Subject has an understanding, ability and willingness to fully comply with study procedures and restrictions.
- Subject has the ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures.
Exclusion Criteria:
- Subjects unable to complete assessments due to language or cognitive impairment
- Subjects with a history of bipolar disorder or psychosis as confirmed by the Mini International Neuropsychiatric Interview (MINI).
- Subject currently has (or had a history within the last 6 months of) a drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) criteria (excluding nicotine).
- Subjects who are currently considered a suicide risk, any subject who has previously made a suicide attempt or who has a prior history of or are currently demonstrating active suicidal ideation.
- Subject has any clinically significant ECG or clinically significant laboratory abnormality (including a positive urine drug screen) at Screening.
- Subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of safety assessments administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that in the Investigator's opinion would prohibit the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol.
- Subjects who do not agree to use adequate and reliable contraception throughout the study.
- Subject previously completed, discontinued or was withdrawn from this study.
- Subject has taken an investigational drug or taken part in a clinical trial within 30 days prior to Screening.
- Subjects treated with antidepressant medication within 4 weeks of screening visit (6 weeks for fluoxetine).
- Subjects with known sensitivity to milnacipran.
- Subjects with liver disease or reduced liver function
- Subjects with obstructive uropathies
- Subjects who consume alcohol in amounts viewed by the Investigator to be contraindicated
- Subjects taking monoamine oxidase inhibitors
- Subjects with uncontrolled narrow angle glaucoma
- Subjects who are pregnant, may become pregnant, or who are nursing
- Subjects with seizure disorders
- Subjects with bleeding disorders or use of other medications that may cause bleeding.
Sites / Locations
- Duke University Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Milnacipran
Arm Description
Open-label flexibly dosed milnacipran
Outcomes
Primary Outcome Measures
Change in Pain Visual Analogue Scale(VAS).
The primary outcome is change in pain VAS from baseline to 12 weeks (baseline score minus 12 week or endpoint score; positive number reflects reduction in pain score). The effect size was calculated using the VAS scores measured on a scale of 0 to 100 mm:
0= absence of pain or no pain noted 100 = worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity.
Secondary Outcome Measures
Change in Knee Society Score (KSS).
KSS measures subjective pain and objective function by joint physical exam. This secondary outcome was the change in Knee Society Score(KSS)from baseline through 12 weeks.
KSS scores measured on a scale of 0 to 100 mm:
0 = absence of pain or no pain noted 100= worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity.
Global Rating of Change
Change in Total Score of Multidimensional Fatigue Inventory (MFI-20)
Measures subjective fatigue.20-item self-report instrument consisting of five scales: General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue.
Each scale contains four items rated on a scale of one to 5 with the scale score of one having the anchor of entirely true and the scale score of 5 having the anchor of no, not true. The five scales were identified through factor analysis and are assumed to measure different aspects of fatigue. Lowest possible total score = 20 (absent fatigue) Highest possible total score = 100 (maximum fatigue) Total mean cumulative scores were reported
Change in the Beck Depression Inventory (BDI-II)
The secondary outcome measure is change in Beck Depression Inventory. The scale for this inventory is:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. The higher the score the degree of depression.
Change in the Montgomery Asberg Depression Rating Scale
Staff-rated assessment of depressive symptoms. Scale is as follows:
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Change in Total Score of State Trait Anxiety Inventory (STAI)
Assessment of subjective symptoms of current anxiety and chronic anxiety. There are 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
Lowest total score is 40 (absent anxiety) Highest total score is 160 (maximum anxiety) Total mean cumulative scores were reported.
Change in Total Score of Short Form-36 (SF-36), Measuring Perceived Quality of Life
Subjective measure of perceived quality of life.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The eight sections are:
vitality,
physical functioning,
bodily pain,
general health perceptions,
physical role functioning,
emotional role functioning,
social role functioning,
mental health
Scale:
0= lowest quality of life 100= high quality of life Higher scores reflect higher quality of life. Total mean cumulative scores were reported.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01780389
Brief Title
Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
Official Title
Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2015
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The current study examines the effects of milnacipran in patients who have chronic persistent knee pain one year or longer after total knee arthroplasty (TKA) to evaluate for a pain-relieving effect.
Detailed Description
The current study proposes to collect pilot data on the utility of open-label milnacipran for the treatment of pain and other outcomes in this unfortunate group of patients with chronic persistent pain after TKA. Among marketed serotonin norepinephrine reuptake inhibitors (SNRIs), milnacipran has a unique property in that it blocks serotonin and norepinephrine reuptake equally. It is plausible that equipotent reuptake inhibition may confer greater analgesic benefit compared to other agents, and in preclinical animal models milnacipran has shown superior effects of ameliorating hyperalgesia and allodynia compared to some other antidepressant drugs. Additionally, milnacipran does not have inhibitory effects on cytochrome P (CYP) 450 enzymes, no binding affinity to neurotransmitter receptors liable to cause adverse events, and simple pharmacokinetics.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain
Keywords
Knee, Pain, Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Milnacipran
Arm Type
Experimental
Arm Description
Open-label flexibly dosed milnacipran
Intervention Type
Drug
Intervention Name(s)
Open-label flexibly dosed milnacipran
Other Intervention Name(s)
Savella
Primary Outcome Measure Information:
Title
Change in Pain Visual Analogue Scale(VAS).
Description
The primary outcome is change in pain VAS from baseline to 12 weeks (baseline score minus 12 week or endpoint score; positive number reflects reduction in pain score). The effect size was calculated using the VAS scores measured on a scale of 0 to 100 mm:
0= absence of pain or no pain noted 100 = worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity.
Time Frame
baseline and endpoint 12 weeks
Secondary Outcome Measure Information:
Title
Change in Knee Society Score (KSS).
Description
KSS measures subjective pain and objective function by joint physical exam. This secondary outcome was the change in Knee Society Score(KSS)from baseline through 12 weeks.
KSS scores measured on a scale of 0 to 100 mm:
0 = absence of pain or no pain noted 100= worst imaginable pain/as bad as can be The higher the score the greater the over all pain intensity.
Time Frame
between baseline and endpoint (12 weeks or early termination)
Title
Global Rating of Change
Time Frame
Endpoint (12 weeks or early termination)
Title
Change in Total Score of Multidimensional Fatigue Inventory (MFI-20)
Description
Measures subjective fatigue.20-item self-report instrument consisting of five scales: General Fatigue, Physical Fatigue, Reduced Activity, Reduced Motivation, and Mental Fatigue.
Each scale contains four items rated on a scale of one to 5 with the scale score of one having the anchor of entirely true and the scale score of 5 having the anchor of no, not true. The five scales were identified through factor analysis and are assumed to measure different aspects of fatigue. Lowest possible total score = 20 (absent fatigue) Highest possible total score = 100 (maximum fatigue) Total mean cumulative scores were reported
Time Frame
Baseline to endpoint (12 weeks or early termination)
Title
Change in the Beck Depression Inventory (BDI-II)
Description
The secondary outcome measure is change in Beck Depression Inventory. The scale for this inventory is:
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. The higher the score the degree of depression.
Time Frame
Baseline to endpoint (12 weeks or early termination)
Title
Change in the Montgomery Asberg Depression Rating Scale
Description
Staff-rated assessment of depressive symptoms. Scale is as follows:
0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression
Time Frame
Between baseline and endpoint (12 weeks or early termination)
Title
Change in Total Score of State Trait Anxiety Inventory (STAI)
Description
Assessment of subjective symptoms of current anxiety and chronic anxiety. There are 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.
Lowest total score is 40 (absent anxiety) Highest total score is 160 (maximum anxiety) Total mean cumulative scores were reported.
Time Frame
baseline and endpoint (12 weeks or early termination)
Title
Change in Total Score of Short Form-36 (SF-36), Measuring Perceived Quality of Life
Description
Subjective measure of perceived quality of life.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The eight sections are:
vitality,
physical functioning,
bodily pain,
general health perceptions,
physical role functioning,
emotional role functioning,
social role functioning,
mental health
Scale:
0= lowest quality of life 100= high quality of life Higher scores reflect higher quality of life. Total mean cumulative scores were reported.
Time Frame
baseline and endpoint (12 weeks or early termination)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is a male or female adult outpatient age 18 or older at the time of consent.
Subject has chronic persistent pain 1 year after TKA without history of new injury, infection, or implant failure.
Subject has VAS > or = 40 mm at screen and baseline visits.
Subject has an understanding, ability and willingness to fully comply with study procedures and restrictions.
Subject has the ability to provide written, personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures.
Exclusion Criteria:
Subjects unable to complete assessments due to language or cognitive impairment
Subjects with a history of bipolar disorder or psychosis as confirmed by the Mini International Neuropsychiatric Interview (MINI).
Subject currently has (or had a history within the last 6 months of) a drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) criteria (excluding nicotine).
Subjects who are currently considered a suicide risk, any subject who has previously made a suicide attempt or who has a prior history of or are currently demonstrating active suicidal ideation.
Subject has any clinically significant ECG or clinically significant laboratory abnormality (including a positive urine drug screen) at Screening.
Subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of safety assessments administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that in the Investigator's opinion would prohibit the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol.
Subjects who do not agree to use adequate and reliable contraception throughout the study.
Subject previously completed, discontinued or was withdrawn from this study.
Subject has taken an investigational drug or taken part in a clinical trial within 30 days prior to Screening.
Subjects treated with antidepressant medication within 4 weeks of screening visit (6 weeks for fluoxetine).
Subjects with known sensitivity to milnacipran.
Subjects with liver disease or reduced liver function
Subjects with obstructive uropathies
Subjects who consume alcohol in amounts viewed by the Investigator to be contraindicated
Subjects taking monoamine oxidase inhibitors
Subjects with uncontrolled narrow angle glaucoma
Subjects who are pregnant, may become pregnant, or who are nursing
Subjects with seizure disorders
Subjects with bleeding disorders or use of other medications that may cause bleeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Davi M Marks, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
24392250
Citation
Marks DM, Bolognesi MP. Open-label milnacipran for patients with persistent knee pain 1 year or longer after total knee arthroplasty: a pilot study. Prim Care Companion CNS Disord. 2013;15(4):PCC.12m01496. doi: 10.4088/PCC.12m01496. Epub 2013 Jul 11.
Results Reference
result
Learn more about this trial
Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)
We'll reach out to this number within 24 hrs